Division of Mucosal Immunology and International Research and Development Center for Mucosal Vaccines, Department of Microbiology and Immunology, The Institute of Medical Science , The University of Tokyo , Tokyo 108-8639 , Japan.
Laboratory of Vaccine Materials , National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) , Osaka 567-0085 , Japan.
Mol Pharm. 2018 Sep 4;15(9):4226-4234. doi: 10.1021/acs.molpharmaceut.8b00648. Epub 2018 Aug 24.
Infections remain a major threat to human lives. To overcome the threat caused by pathogens, mucosal vaccines are considered a promising strategy. However, no inactivated and/or subunit mucosal vaccine has been approved for human use, largely because of the lack of a safe and effective mucosal adjuvant. Here, we show that enzymatically synthesized polymeric caffeic acid (pCA) can act as a potent mucosal adjuvant in mice. Intranasal administration of ovalbumin (OVA) in combination with pCA resulted in the induction of OVA-specific mucosal IgA and serum IgG, especially IgG1. Importantly, pCA was synthesized from caffeic acid and horseradish peroxidase from coffee beans and horseradish, respectively, which are commonly consumed. Therefore, pCA is believed to be a highly safe material. In fact, administration of pCA did not show distinct toxicity in mice. These data indicate that pCA has merit for use as a mucosal adjuvant for nasal vaccine formulations.
感染仍然是对人类生命的主要威胁。为了克服病原体造成的威胁，黏膜疫苗被认为是一种很有前途的策略。然而，由于缺乏安全有效的黏膜佐剂，目前还没有一种灭活和/或亚单位黏膜疫苗被批准用于人体。在这里，我们表明，酶合成的聚合咖啡酸（pCA）可以作为一种有效的黏膜佐剂在小鼠体内发挥作用。与 pCA 联合鼻内给予卵清蛋白（OVA）可诱导 OVA 特异性黏膜 IgA 和血清 IgG，特别是 IgG1。重要的是，pCA 是由咖啡豆和辣根中的咖啡酸和辣根过氧化物酶分别合成的，这些都是常见的食用物质。因此，pCA 被认为是一种非常安全的材料。事实上，pCA 的给药在小鼠中没有表现出明显的毒性。这些数据表明，pCA 作为鼻用疫苗制剂的黏膜佐剂具有一定的应用价值。
